symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LIPO,0.98,0,6432,5687861,0,0.85-7.72,0.015,Lipella Pharmaceuticals Inc.,USD,0001347242,,,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.lipella.com,"Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.","Dr. Jonathan  Kaufman M.B.A., Ph.D.",Healthcare,US,5,412-894-1853,7800 Susquehanna St.,Pittsburgh,PA,15208,,0,https://financialmodelingprep.com/image-stock/LIPO.png,2022-12-19,False,False,True,False,False
